Zacks Investment Research downgraded shares of Aclaris Therapeutics (NASDAQ:ACRS) from a hold rating to a sell rating in a report released on Wednesday morning.

According to Zacks, “Aclaris Therapeutics, Inc. is a specialty pharmaceutical company. The Company is focused on identifying, developing and commercializing drugs to met needs in dermatology. Its drug candidate consists of A-101, a high-concentration hydrogen peroxide topical solution which is being developed as a prescription treatment for seborrheic keratosis a common non-malignant skin tumor and A-102, a proprietary topical gel dosage form of hydrogen peroxide for the treatment of SK and common warts which are in different clinical trial. Aclaris Therapeutics, Inc. is headquartered in Malvern, Pennsylvania. “

A number of other research firms have also commented on ACRS. BidaskClub lowered shares of Aclaris Therapeutics from a sell rating to a strong sell rating in a research note on Saturday, January 19th. Cantor Fitzgerald set a $50.00 price objective on shares of Aclaris Therapeutics and gave the stock a buy rating in a research note on Friday, December 21st. Finally, ValuEngine lowered shares of Aclaris Therapeutics from a hold rating to a sell rating in a research note on Wednesday, January 2nd. Three research analysts have rated the stock with a sell rating and three have assigned a buy rating to the stock. Aclaris Therapeutics has an average rating of Hold and a consensus target price of $35.94.

Aclaris Therapeutics stock opened at $5.63 on Wednesday. Aclaris Therapeutics has a 52 week low of $5.49 and a 52 week high of $21.97. The company has a market capitalization of $242.75 million, a P/E ratio of -2.25 and a beta of 1.24.

Several large investors have recently modified their holdings of the business. BlackRock Inc. boosted its stake in shares of Aclaris Therapeutics by 43.8% during the 4th quarter. BlackRock Inc. now owns 3,620,835 shares of the biotechnology company’s stock valued at $26,759,000 after buying an additional 1,103,423 shares during the period. D. E. Shaw & Co. Inc. boosted its stake in shares of Aclaris Therapeutics by 71.6% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 2,278,364 shares of the biotechnology company’s stock valued at $16,837,000 after buying an additional 950,781 shares during the period. Sofinnova Investments Inc. boosted its stake in shares of Aclaris Therapeutics by 24.2% during the 4th quarter. Sofinnova Investments Inc. now owns 1,911,573 shares of the biotechnology company’s stock valued at $14,127,000 after buying an additional 372,093 shares during the period. Broadfin Capital LLC acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at $13,875,000. Finally, MFN Partners Management LP acquired a new stake in shares of Aclaris Therapeutics during the 4th quarter valued at $11,085,000. 95.20% of the stock is owned by institutional investors.

About Aclaris Therapeutics

Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.

Further Reading: What are no-load funds?

Get a free copy of the Zacks research report on Aclaris Therapeutics (ACRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.